Ectoine-containing cream in the treatment of mild to moderate atopic dermatitis: A randomised, comparator-controlled, intra-individual double-blind, multi-center trial

Skin Pharmacology and Physiology

Volumn 27, Issue 2, 2014, Pages 57-65

  Marini, A ^a   Reinelt, K ^b   Krutmann, J ^a   Bilstein, A ^b  

^a IUF LEIBNIZ RESEARCH INSTITUTE FOR ENVIRONMENTAL MEDICINE   (Germany)

^b BITOP AG   (Germany)

Author keywords

Atopic dermatitis; Ectoine; Osmolytes; Topical treatment

Indexed keywords

DERMATOLOGICAL AGENT; ECTOINE; EHK 0201; EHK02 01; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; BRONCHITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PAPULE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN; VISUAL ANALOG SCALE; YOUNG ADULT; CLINICAL FEATURE; COMMON COLD; DISEASE SEVERITY; DRUG TOLERABILITY; INVESTIGATOR GLOBAL ASSESSMENT; LICHENOID ERUPTION; SCORING ATOPIC DERMATITIS; SCORING SYSTEM; SKIN BURNING SENSATION; SKIN DISEASE ASSESSMENT; SKIN EDEMA; SKIN FUNCTION; TREATMENT DURATION;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AMINO ACIDS, DIAMINO; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PRURITUS; SKIN CREAM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893054091     PISSN: 16605527     EISSN: 16605535     Source Type: Journal    
DOI: 10.1159/000351381     Document Type: Article

References (30)

1. Akdis CA, Akdis M, Bieber T, Bindslev-Jen-sen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006;118:152-169. (Pubitemid 43946480)
2. Williams HC: Clinical practice. Atopic dermatitis. N Engl J Med 2005;352:2314-2324.
3. Breuer K, Werfel T, Kapp A: Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. Am J Clin Dermatol 2005;6:65-77. (Pubitemid 40529749)
4. Chen SL, Yan J, Wang FS: Two topical calci-neurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-anal-ysis of randomized clinical trials. J Dermato-log Treat 2010;21:144-156.
5. Frankel HC, Qureshi AA: Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. Am J Clin Dermatol 2012;13:113-123.
6. Shams K, Grindlay DJ, Williams HC: What's new in atopic eczema? An analysis of systematic reviews published in 2009-2010. Clin Exp Dermatol 2011;36:573-577.
7. Galinski EA, Pfeffer HP, Trüpper HG: 1, 4, 5, 6-Tetrahydro-2-methyl- 4-pyrimidine-carboxylic acid. A novel cyclic amino acid from halophilic phototropic bacteria of the genus Ectothiorhodospira. Eur J Biochem 1995;149:135-139.
8. Lentzen G, Schwarz T: Extremolytes: natural compounds from extremophiles for versatile applications. Appl Microbiol Biotechnol 2006;72:623-634. (Pubitemid 44454921)
9. Yancey PH: Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J Exp Biol 2005;208:2819-2830. (Pubitemid 41265173)
10. Graf R, Anzali S, Buenger J, Pfluecker F, Driller H: The multifunctional role of ectoine as a natural cell protectant. Clin Dermatol 2008; 26:326-333.
11. Lentzen G, Schwarz T: Extremolytes: natural compounds from extremophiles for versatile applications. Appl Microbiol Biotechnol 2006;72:623-634. (Pubitemid 44454921)
12. Dirschka T: Doppelblinde, randomisierte monozentrische Untersuchung zur Wirksam-keit und Verträglichkeit einer ectoinhaltigen Crème bei chronischer Plaque-Psoriasis; a study report, Wuppertal, 2008.
13. Heffernan M, Houshmand E: Treatment options for atopic dermatitis. US Spec Popul Pe-diatr Rev 2006:57-58.
14. Patrizi A, Raone B, Neri I: Atopiclair. Expert Opin Pharmacother 2009;10:1223-1230.
15. Veraldi S, De Micheli P, Schianchi R, Lunar-don L: Treatment of pruritus in mild-to-moderate atopic dermatitis with a topical non-ste-roidal agent. J Drugs Dermatol 2009;8:537-539.
16. TM) is in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr 2008;152: 854-859.
17. Abramovits W, Boguniewicz M, Adult Atopi-clair Study Group: A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006;5:236-244.
18. Patrizi A, Capitanio B, Neri I, Giacomini F, Sinagra JL, Raone B, Berardesca E: A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol 2008;19:619-625.
19. European Task Force on Atopic Dermatitis: Severity scoring of atopic dermatitis: the SCORAD Index. Dermatology 1993;186:23-31.
20. Charman C, Chambers C, Williams H: Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol 2003;120: 932-941. (Pubitemid 36702900)
21. Wellek S: Statistische Methoden zum Nach-weis von Äquivalenz. Stuttgart, Fischer, 1994.
22. Heinrich U, Garbe B, Tronnie H: In vivo assessment of ectoin: a randomized, vehicle-controlled clinical trial. Skin Pharmacol Physiol 2007;20:211-218. (Pubitemid 47000425)
23. Bünger J, Degwert J, Driller H: The protective function of compatible solute ectoin on the skin, skin cells and its biomolecules with respect to UV radiation, immunosuppression and membrane damage. IFSCC Mag 2001;4:127-131.
24. Beyer N, Driller H, Bünger J: Ectoin-an innovative, multi-functional active substance for the cosmetic industry. SÖFW J 2000;126:27-29.
25. Bünger J, Driller H: Ectoin: An effective natural substance to prevent UVA-induced premature photoaging. Skin Pharmacol Physiol 2004;17:232-237. (Pubitemid 39370254)
26. Bünger J: Ectoine added protection and care for the skin. Eurocosmetics 1999;7:22-24.
27. Grether-Beck S, Timmer A, Felsner I, Brenden H, Brammertz D, Krutmann J: Ultraviolet A-induced signaling involves a ceramide-mediat-ed autocrine loop leading to ceramide de novo synthesis. J Invest Dermatol 2005;125:545-553.
28. Vejlsgaard GL, Ralfkiaer E, Avnstorp C, Cza-jkowski M, Marlin SD, Rothlein R: Kinetics and characterization of intercellular adhesion molecule-1 (ICAM-1) expression on kerati-nocytes in various inflammatory skin lesions and malignant cutaneous lymphomas. J Am Acad Dermatol 1989;20:782-790. (Pubitemid 19127915)
29. Sydlik U, Gallitz I, Albrecht C, Abel J, Krut-mann J, Unfried K: The compatible solute ec-toine protects against nanoparticle-induced neutrophilic lung inflammation. Am J Respir Crit Care Med 2009;180:29-35.
30. Sydlik U, Peuschel H, Paunel-Görgülü A, Keymel S, Krämer U, Weissenberg A, Kroker M, Seghrouchni S, Heiss C, Windolf J, Bilstein A, Kelm M, Krutmann J, Unfried K: Recovery of neutrophil apoptosis by ectoine: a new strategy against lung inflammation. Eur Respir J 2013;41:1-11.